capricor
therapeutics
present
wainwright
annual
global
investment
conference
los
angeles
globe
newswire
capricor
therapeutics
capricor
nasdaq
capr
biotechnology
company
focused
development
cell
therapeutics
treatment
prevention
diseases
announced
today
linda
marb√°n
ceo
capricor
therapeutics
present
virtual
wainwright
annual
global
investment
conference
september
wainwright
annual
global
investment
conference
details
date
tuesday
september
presentation
time
et
pt
webcast
https
webcast
capr
please
visit
investor
relations
section
company
website
archived
webcasts
investor
materials
available
http
news
events
capricor
therapeutics
capricor
therapeutics
nasdaq
capr
biotechnology
company
focused
discovery
development
commercialization
cell
therapeutics
treatment
prevention
diseases
capricor
lead
candidate
allogeneic
cell
therapy
currently
clinical
development
treatment
duchenne
muscular
dystrophy
capricor
also
investigating
field
extracellular
vesicles
exploring
potential
candidates
treat
prevent
variety
disorders
developing
two
potential
vaccines
part
exosome
platform
information
visit
follow
company
facebook
instagram
twitter
cautionary
note
regarding
statements
statements
press
release
regarding
efficacy
safety
intended
utilization
capricor
product
candidates
initiation
conduct
size
timing
results
discovery
efforts
clinical
trials
pace
enrollment
clinical
trials
plans
regarding
regulatory
filings
future
research
clinical
trials
regulatory
developments
involving
products
including
ability
obtain
regulatory
approvals
otherwise
bring
products
market
plans
regarding
current
future
collaborative
activities
ownership
commercial
rights
scope
duration
validity
enforceability
intellectual
property
rights
future
royalty
streams
revenue
projections
expectations
respect
expected
use
proceeds
recently
completed
offerings
anticipated
effects
offerings
statements
capricor
management
team
future
expectations
beliefs
goals
plans
prospects
constitute
statements
within
meaning
private
securities
litigation
reform
act
statements
statements
historical
fact
including
statements
containing
words
believes
plans
could
anticipates
expects
estimates
target
would
similar
expressions
also
considered
statements
number
important
factors
could
cause
actual
results
events
differ
materially
indicated
statements
information
risks
may
impact
capricor
business
set
forth
capricor
annual
report
form
year
ended
december
filed
securities
exchange
commission
march
quarterly
report
form
quarter
ended
june
filed
securities
exchange
commission
august
statements
press
release
based
information
available
capricor
date
hereof
capricor
assumes
obligation
update
statements
investigational
new
drug
approved
indications
none
capricor
candidates
approved
clinical
investigation
information
please
contact
media
contact
caitlin
kasunich
kcsa
strategic
communications
ckasunich
investor
contact
joyce
allaire
lifesci
advisors
llc
jallaire
